Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research

Marius M Hoeper; Carolyn S P Lam; Jean-Luc Vachiery; Johann Bauersachs; Christian Gerges; Irene M Lang; Diana Bonderman; Karen M Olsson; J Simon R Gibbs; Peter Dorfmuller; Marco Guazzi; Nazzareno Galiè; Alessandra Manes; M Louis Handoko; Anton Vonk-Noordegraaf; Mareike Lankeit; Stavros Konstantinides; Rolf Wachter; Christian Opitz; Stephan Rosenkranz

doi:10.1093/eurheartj/ehw597

Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research

Marius M Hoeper, Carolyn S P Lam, Jean-Luc Vachiery, Johann Bauersachs, Christian Gerges, Irene M Lang, Diana Bonderman, Karen M Olsson, J Simon R Gibbs, Peter Dorfmuller, Marco Guazzi, Nazzareno Galiè, Alessandra Manes, M Louis Handoko, Anton Vonk-Noordegraaf, Mareike Lankeit, Stavros Konstantinides, Rolf Wachter, Christian Opitz, Stephan Rosenkranz

Research output: Contribution to journal › Review article › peer-review

Abstract

Heart failure (HF) with preserved ejection fraction (HFpEF) is a common disease affecting the elderly in particular. Up to 80% of these patients develop pulmonary hypertension (PH), which is associated with worse symptoms and increased mortality.1 It is a matter of concern that drugs approved for pulmonary arterial hypertension (PAH) are sometimes used in such patients despite insufficient data for their safety and efficacy. On the other hand, the impact of PH and right ventricular (RV) dysfunction on morbidity and mortality in HFpEF call for proper attention both at the clinical and scientific level. Here we discuss the clinical problem, pathophysiology, diagnostic shortfalls, gaps in evidence, and future strategies for PH-HFpEF.

Original language	English
Pages (from-to)	2869-2873
Number of pages	5
Journal	European heart journal
Volume	38
Issue number	38
DOIs	https://doi.org/10.1093/eurheartj/ehw597
Publication status	Published - 7 Oct 2017
Externally published	Yes

Keywords

Biomedical Research/methods
Global Health
Heart Failure/complications
Humans
Hypertension, Pulmonary/etiology
Morbidity/trends
Stroke Volume/physiology
Survival Rate/trends

Access to Document

10.1093/eurheartj/ehw597

Cite this

Hoeper, M. M., Lam, C. S. P., Vachiery, J.-L., Bauersachs, J., Gerges, C., Lang, I. M., Bonderman, D., Olsson, K. M., Gibbs, J. S. R., Dorfmuller, P., Guazzi, M., Galiè, N., Manes, A., Handoko, M. L., Vonk-Noordegraaf, A., Lankeit, M., Konstantinides, S., Wachter, R., Opitz, C., & Rosenkranz, S. (2017). Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research. European heart journal, 38(38), 2869-2873. https://doi.org/10.1093/eurheartj/ehw597

@article{0a47e43b7f1240f7a36c2bd7ee49085c,

title = "Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research",

abstract = "Heart failure (HF) with preserved ejection fraction (HFpEF) is a common disease affecting the elderly in particular. Up to 80% of these patients develop pulmonary hypertension (PH), which is associated with worse symptoms and increased mortality.1 It is a matter of concern that drugs approved for pulmonary arterial hypertension (PAH) are sometimes used in such patients despite insufficient data for their safety and efficacy. On the other hand, the impact of PH and right ventricular (RV) dysfunction on morbidity and mortality in HFpEF call for proper attention both at the clinical and scientific level. Here we discuss the clinical problem, pathophysiology, diagnostic shortfalls, gaps in evidence, and future strategies for PH-HFpEF.",

keywords = "Biomedical Research/methods, Global Health, Heart Failure/complications, Humans, Hypertension, Pulmonary/etiology, Morbidity/trends, Stroke Volume/physiology, Survival Rate/trends",

author = "Hoeper, {Marius M} and Lam, {Carolyn S P} and Jean-Luc Vachiery and Johann Bauersachs and Christian Gerges and Lang, {Irene M} and Diana Bonderman and Olsson, {Karen M} and Gibbs, {J Simon R} and Peter Dorfmuller and Marco Guazzi and Nazzareno Gali{\`e} and Alessandra Manes and Handoko, {M Louis} and Anton Vonk-Noordegraaf and Mareike Lankeit and Stavros Konstantinides and Rolf Wachter and Christian Opitz and Stephan Rosenkranz",

note = "Publisher Copyright: {\textcopyright} The Author 2016.",

year = "2017",

month = oct,

day = "7",

doi = "10.1093/eurheartj/ehw597",

language = "English",

volume = "38",

pages = "2869--2873",

number = "38",

}

Hoeper, MM, Lam, CSP, Vachiery, J-L, Bauersachs, J, Gerges, C, Lang, IM, Bonderman, D, Olsson, KM, Gibbs, JSR, Dorfmuller, P, Guazzi, M, Galiè, N, Manes, A, Handoko, ML, Vonk-Noordegraaf, A, Lankeit, M, Konstantinides, S, Wachter, R, Opitz, C & Rosenkranz, S 2017, 'Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research', European heart journal, vol. 38, no. 38, pp. 2869-2873. https://doi.org/10.1093/eurheartj/ehw597

TY - JOUR

T1 - Pulmonary hypertension in heart failure with preserved ejection fraction

T2 - a plea for proper phenotyping and further research

AU - Hoeper, Marius M

AU - Lam, Carolyn S P

AU - Vachiery, Jean-Luc

AU - Bauersachs, Johann

AU - Gerges, Christian

AU - Lang, Irene M

AU - Bonderman, Diana

AU - Olsson, Karen M

AU - Gibbs, J Simon R

AU - Dorfmuller, Peter

AU - Guazzi, Marco

AU - Galiè, Nazzareno

AU - Manes, Alessandra

AU - Handoko, M Louis

AU - Vonk-Noordegraaf, Anton

AU - Lankeit, Mareike

AU - Konstantinides, Stavros

AU - Wachter, Rolf

AU - Opitz, Christian

AU - Rosenkranz, Stephan

PY - 2017/10/7

Y1 - 2017/10/7

N2 - Heart failure (HF) with preserved ejection fraction (HFpEF) is a common disease affecting the elderly in particular. Up to 80% of these patients develop pulmonary hypertension (PH), which is associated with worse symptoms and increased mortality.1 It is a matter of concern that drugs approved for pulmonary arterial hypertension (PAH) are sometimes used in such patients despite insufficient data for their safety and efficacy. On the other hand, the impact of PH and right ventricular (RV) dysfunction on morbidity and mortality in HFpEF call for proper attention both at the clinical and scientific level. Here we discuss the clinical problem, pathophysiology, diagnostic shortfalls, gaps in evidence, and future strategies for PH-HFpEF.

AB - Heart failure (HF) with preserved ejection fraction (HFpEF) is a common disease affecting the elderly in particular. Up to 80% of these patients develop pulmonary hypertension (PH), which is associated with worse symptoms and increased mortality.1 It is a matter of concern that drugs approved for pulmonary arterial hypertension (PAH) are sometimes used in such patients despite insufficient data for their safety and efficacy. On the other hand, the impact of PH and right ventricular (RV) dysfunction on morbidity and mortality in HFpEF call for proper attention both at the clinical and scientific level. Here we discuss the clinical problem, pathophysiology, diagnostic shortfalls, gaps in evidence, and future strategies for PH-HFpEF.

KW - Biomedical Research/methods

KW - Global Health

KW - Heart Failure/complications

KW - Humans

KW - Hypertension, Pulmonary/etiology

KW - Morbidity/trends

KW - Stroke Volume/physiology

KW - Survival Rate/trends

U2 - 10.1093/eurheartj/ehw597

DO - 10.1093/eurheartj/ehw597

M3 - Review article

C2 - 28011705

SN - 0195-668X

VL - 38

SP - 2869

EP - 2873

JO - European heart journal

JF - European heart journal

IS - 38

ER -

Pulmonary hypertension in heart failure with preserved ejection fraction: a plea for proper phenotyping and further research

Abstract

Keywords

Access to Document

Fingerprint

Cite this